Trials / Completed
CompletedNCT02667483
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- Male
- Age
- 5 Years – 10 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-5141b | DS-5141b, Subcutaneous injection |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2020-10-20
- Completion
- 2020-10-20
- First posted
- 2016-01-29
- Last updated
- 2024-03-07
- Results posted
- 2024-03-07
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02667483. Inclusion in this directory is not an endorsement.